VIVE
vs
O
OMX Stockholm 30
VIVE
Over the past 12 months, VIVE has underperformed OMX Stockholm 30, delivering a return of -65% compared to the OMX Stockholm 30's +31% growth.
Stocks Performance
VIVE vs OMX Stockholm 30
Performance Gap
VIVE vs OMX Stockholm 30
Performance By Year
VIVE vs OMX Stockholm 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Vivesto AB
Glance View
Oasmia Pharmaceutical AB engages in the research and development of drugs. The company is headquartered in Solna, Stockholm. The company went IPO on 2005-01-01. The firm has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
